GeoVax Labs Inc.

Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax

Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax

First Woman President and CEO of MSM and Internationally Recognized Health Equity Advocate Joins in GeoVax Special Advisory Role

ATLANTA, GA, Dec. 20, 2022 (GLOBE NEWSWIRE) -- via  -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the appointment of Valerie Montgomery Rice, MD, FACOG, Morehouse School of Medicine President and CEO, as Special Advisor to the Chairman/CEO and Board of Directors of GeoVax.

Dr. Montgomery Rice brings GeoVax exceptional expertise and highly recognized experience at the highest levels of healthcare leadership, patient care, biomedical research, and public health policy.

“We are delighted Dr. Montgomery Rice is joining in this unique advisory role for GeoVax’s growing ecosystem of outstanding executives, advisors, board members, scientists, and partners,” said David Dodd, GeoVax Chairman and CEO. “Her organizational management acumen and career-long dedication to advance medical training, health equity and other critical areas of public health, will add dimension to our initiatives to expand access to our investigational vaccines and immunotherapies against life-threatening infectious diseases and cancers.”  

Dr. Montgomery Rice has been a driving force behind research, education and care that closes equity gaps in healthcare, including women’s health. She currently serves as President and Chief Executive Officer of the Morehouse School of Medicine (MSM) in Atlanta and is the first woman in the institution’s history to serve in this role. At MSM, she has also served as Dean and Executive Vice President and professor of Obstetrics and Gynecology. Prior to MSM, Dr. Montgomery Rice held a number of faculty and leadership positions at Meharry Medical College in Nashville, including professor and chair in the Department of Obstetrics and Gynecology, Dean and Senior Vice President of Meharry Medical College’s School of Medicine, and Program Director of the OB-GYN Residency Training Program and Founding Director of the Center for Women’s Health Research, one of the nation’s first research centers devoted to studying diseases that disproportionately impact women of color. Dr. Montgomery Rice also served in faculty and leadership roles at University of Kansas School of Medicine, Vanderbilt University Medical Center, and Henry Ford Medical Center.

Dr. Montgomery Rice holds memberships in various organizations and participates on several boards. She is an Advisory Board Member of the Historically Black Colleges and Universities Capital Financing Advisory Board. She also serves on the board of directors for UnitedHealth Group, Wellpath, 23&Me, Nemours, CARE USA, Josiah Macy Jr. Foundation, and the Moffit Cancer Center. In 2021, Governor Brian Kemp appointed Dr. Montgomery Rice to the Georgia Commission on Women, where she lends her depth of knowledge and expertise as a women’s health researcher to improve the life of women and their families in Georgia. In March 2022, President Joe Biden appointed Dr. Montgomery Rice to the President’s Committee on the National Medal of Science.

“I am particularly excited about GeoVax’s innovative programs focused on providing the public protection from the most pressing and emerging infectious disease threats,” said Dr. Montgomery Rice. “I look forward to helping GeoVax as the company progresses its vaccine and immunology programs toward patients.”

Dedicated to the creation and advancement of health equity, Dr. Montgomery Rice’s career has been recognized with numerous accolades and honors, notably, the Horatio Alger Award, the National Human Relations Award from the American Jewish Committee Atlanta, the Dean Griffin Community Service Award from the Georgia Institute of Technology, Girls Inc. 2019 Smart Award, the National Medical Association OB/GYN 2019 Legend of the Section Award, the Turknett Leadership Character Award, Visions of Excellence Award from the Atlanta Business League, the Links Incorporated Co-Founders Award, the Trumpet Vanguard Award, the Dorothy I. Height Crystal Stair Award, National Coalition of 100 Black Women - Women of Impact, YWCA – Women of Achievement of Atlanta and Nashville, American Medical Women’s Association Elizabeth Blackwell Medal, and Working Mother Media Multicultural Women’s Legacy Award. 

Dr. Montgomery Rice holds a bachelor’s degree in chemistry from the Georgia Institute of Technology, a medical degree from Harvard Medical School, an honorary degree from the University of Massachusetts Medical School, and a Doctor of Humane Letters honorary degree from Rush University.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in two Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a single-dose, COVID-19 vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient. In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website:

Media Relations Contact:

Gina Cestari

6 Degrees

917-797-7904 

Investor Relations Contact:

Rich Cockrell

CG Capital

404-736-3838 

tal



EN
20/12/2022

Reports on GeoVax Labs Inc.

 PRESS RELEASE

GeoVax Receives Notice of Allowance For Cancer Vaccine Patent

GeoVax Receives Notice of Allowance For Cancer Vaccine Patent Adds to Growing Portfolio of Intellectual Property Assets ATLANTA, Ga., Dec. 09, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for Patent Application No. 17/876,682 to GeoVax, titled “Vaccinia Viral Vectors Encoding Chimeric Virus Like Particles.” The allowed claims add to GeoVax’s intellectual property protection related...

 PRESS RELEASE

GeoVax to Present at the Noble Capital Markets Twentieth Annual Emergi...

GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference ATLANTA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO, David Dodd, will present at NobleCon20 - the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference taking place December 2-5, 2024 in Boca Raton, FL. Presentation Details:Speaker: David Dodd, Chairman & CEO Date/Time: December 3, 2024, 11:30 am ET Location: Flor...

 PRESS RELEASE

GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Tri...

GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia GEO-CM04S1 Improved Immune Response vs mRNA Vaccine ATLANTA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the completion of an interim data review by the Data Safety Monitoring Board (DSMB) for the ongoing Phase 2 clinical trial of GEO-CM04S1, GeoVax’s dual-antigen next-generation COVID-19 vaccine, a...

 PRESS RELEASE

GeoVax Reports Third Quarter 2024 Financial Results and Provides Busin...

GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024 Gedeptin® on track to advance into Phase 2 clinical trial for first recurrent head and neck cancer in the first half of 2025 GEO-MVA Mpox vaccine advancing with cGMP clinical batch anticipated during fourth quarter 2024 Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, ...

 PRESS RELEASE

GeoVax to Report Third Quarter 2024 Financial Results and Provide Corp...

GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024 GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to pro...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch